We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO ... A report said Friday that the negotiation process was in line with outgoing president Joe Biden’s signature ...

Novo Nordisk is facing serious pressure from a ... were confident that Wegovy is actually more effective than the other product. As of Dec. 4, there's no reason for it to be that confident ...

Medicare plans to negotiate prices for Novo Nordisk products Ozempic (an injection to control diabetes), Wegovy (an injection more designed for weight loss), and Rybelsus (a pill for diabetes).

In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials ... should all contribute to the bottom line with full production, marketing, and sales integration ...